Title | Disrupted excitation-inhibition balance in cognitively normal individuals at risk of Alzheimer's disease. |
Publication Type | Journal Article |
Year of Publication | 2023 |
Authors | Fortel, I, Zhan, L, Ajilore, O, Wu, Y, Mackin, S, Leow, A |
Journal | bioRxiv |
Date Published | 2023 Aug 22 |
Abstract | BACKGROUND: Sex differences impact Alzheimer's disease (AD) neuropathology, but cell-to-network level dysfunctions in the prodromal phase are unclear. Alterations in hippocampal excitation-inhibition balance (EIB) have recently been linked to early AD pathology. OBJECTIVE: Examine how AD risk factors (age, APOE-ɛ4, amyloid-β) relate to hippocampal EIB in cognitively normal males and females using connectome-level measures. METHODS: Individuals from the OASIS-3 cohort (age 42-95) were studied (N = 437), with a subset aged 65+ undergoing neuropsychological testing (N = 231). RESULTS: In absence of AD risk factors (APOE-ɛ4/Aβ+), whole-brain EIB decreases with age more significantly in males than females (p = 0.021, β = -0.007). Regression modeling including APOE-ɛ4 allele carriers (Aβ-) yielded a significant positive AGE-by-APOE interaction in the right hippocampus for females only (p = 0.013, β = 0.014), persisting with inclusion of Aβ+ individuals (p = 0.012, β = 0.014). Partial correlation analyses of neuropsychological testing showed significant associations with EIB in females: positive correlations between right hippocampal EIB with categorical fluency and whole-brain EIB with the trail-making test (p CONCLUSION: Sex differences in EIB emerge during normal aging and progresses differently with AD risk. Results suggest APOE-ɛ4 disrupts hippocampal balance more than amyloid in females. Increased excitation correlates positively with neuropsychological performance in the female group, suggesting a duality in terms of potential beneficial effects prior to cognitive impairment. This underscores the translational relevance of APOE-ɛ4 related hyperexcitation in females, potentially informing therapeutic targets or early interventions to mitigate AD progression in this vulnerable population. |
DOI | 10.1101/2023.08.21.554061 |
Alternate Journal | bioRxiv |
PubMed ID | 37662359 |
PubMed Central ID | PMC10473582 |
Grant List | P30 AG066444 / AG / NIA NIH HHS / United States R01 AG043434 / AG / NIA NIH HHS / United States U01 AG068057 / AG / NIA NIH HHS / United States P01 AG003991 / AG / NIA NIH HHS / United States P01 AG026276 / AG / NIA NIH HHS / United States R01 EB009352 / EB / NIBIB NIH HHS / United States R01 AG071243 / AG / NIA NIH HHS / United States RF1 MH125928 / MH / NIMH NIH HHS / United States UL1 TR000448 / TR / NCATS NIH HHS / United States UL1 TR002345 / TR / NCATS NIH HHS / United States |